What is Silence Therapeutics plc (SLN) stock price today?

Silence Therapeutics plc (SLN) is currently trading at $9.80, down 0.36% today.

What is SLN P/E ratio?

Silence Therapeutics plc's P/E ratio is -2.57. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is SLN return on equity (ROE)?

Silence Therapeutics plc's return on equity (ROE) is -106.94%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Silence Therapeutics plc's market cap?

Silence Therapeutics plc has a market capitalization of $462.66M.

NASDAQ · Biotechnology

Silence Therapeutics plc (SLN) Stock

$9.80 -0.36% NASDAQ: SLN Healthcare

Valuation

Metric	Value
Price	$9.80
Market Cap	$462.66M
P/E Ratio	-2.57
P/B Ratio	4.01
P/S Ratio	753.15
EPS (TTM)	$-5.67
52-Week High	$17.58
52-Week Low	$4.19
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-106.94%
ROA	-56.34%
ROCE	-71.33%
Gross Margin	51.00%
Operating Margin	-9000.00%
Net Margin	-8900.00%
Debt/Equity	0.00
Current Ratio	7.42

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$12.0M	$18.0M	$25.0M	$43.0M	$1.0M
Operating Profit	$-46.0M	$-50.0M	$-50.0M	$-63.0M	$-90.0M
Net Profit	$-39.0M	$-41.0M	$-43.0M	$-45.0M	$-89.0M
EPS	$-1.35	$-3.78	$-3.48	$-2.37	$-5.67
Op Margin	-369.0%	-281.9%	-195.5%	-146.4%	-16056.0%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$96.0M	$108.0M	$95.0M	$162.0M	$131.0M
Total Liabilities	$88.0M	$85.0M	$77.0M	$55.0M	$69.0M
Cash	$74.0M	$55.0M	$54.0M	$97.0M	$11.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Silence Therapeutics to Participate in Three September Investor Conferences Business Wire · Sep 2, 2026 Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs Business Wire · Aug 14, 2026 Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering Business Wire · Aug 12, 2026 Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial MarketBeat · Aug 11, 2026 Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares Business Wire · Aug 10, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$9.0M	$-57.0M	$-39.0M	$-54.0M	$-62.0M
Investing Cash Flow	$10.0M	$-21.0M	$16.0M	$-18.0M	$-48.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$62.0M	$-33.0M	$-1.0M	$42.0M	$-110.0M
Free Cash Flow	$7.0M	$-58.0M	$-39.0M	$-54.0M	$-62.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.19
EV / EBITDA	-6.48
FCF Yield	-9.15%
Quick Ratio	7.42
Interest Coverage	—
Return 1Y	90.56%
Return 3Y	4.20%
Return 5Y	-53.53%

Ownership

Insiders Held7.97%

Institutions Held44.61%

Institutions Float Held48.47%

Institutional Holder	Shares	Report Date
Siren, L.L.C.	3,311,438	2026-06-30
TCG Crossover Management, LLC	3,033,560	2026-06-30
Redmile Group, LLC	2,164,777	2026-06-30
Nantahala Capital Management, LLC	1,346,731	2026-06-30
Citadel Advisors Llc	1,329,625	2026-06-30

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADRXADARx Pharmaceuticals, Inc.	$17.65	-0.28%	—	$1.89B	0.00%
ARCTArcturus Therapeutics Holdings Inc.	$10.34	-8.25%	-3.91	$293.89M	0.00%
ARWRArrowhead Pharmaceuticals, Inc.	$55.90	-4.44%	-28.66	$7.90B	0.00%
BNTCBenitec Biopharma Inc.	$8.11	-4.14%	-9.79	$282.90M	0.00%
IONSIonis Pharmaceuticals, Inc.	$42.94	-2.67%	-12.57	$7.14B	0.00%

About Silence Therapeutics plc

Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.

Silence Therapeutics plc is headquartered in GB.

Silence Therapeutics plc (SLN) stock trades at $9.80 with a market capitalization of $462.66M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.57, reflecting a net loss over the last twelve months, price-to-book of 4.01, price-to-sales of 753.15. Over the past 52 weeks the stock has ranged between $4.19 and $17.58, and currently trades 44.3% below its 52-week high.

On profitability, Silence Therapeutics plc generates a return on equity (ROE) of -106.94% (negative, reflecting a net loss), return on capital employed of -71.33%, an operating margin of -9000.00%, a net profit margin of -8900.00%.

Official website: www.silence-therapeutics.com